Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Combining Epigenetic and Immunotherapy in Cancer: Molecular Mechanisms

The Indonesian Biomedical Journal · Vol. 15 No. 1 (2023) · hlm. 1–24

DOI
10.18585/inabj.v15i1.2062
ISSN
2085-3297, 2355-9179
Terbit
2023-02-23
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Immunotherapy, particularly the idea of immune checkpoint blockage is currently draw much attention in cancer treatment. It has been approved as an adjuvant, however, it cannot be a single cancer treatment.CONTENT: The discovery of the basic ligand-receptor interactions between immune and cancer cells inside the tumor microenvironment has led to the current interest in immunotherapy, specifically immune checkpoint inhibition. Different ligands produced by cancer cells interact with immune cells' surface receptors, activating inhibitory pathways, such programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1), that cause immune cells to become immunologically tolerant. On the other side, epigenetic modulators also play a critical role in enhancing the tumor microenvironment and regaining immunological recognition and immunogenicity. Some findings showed that such immune suppression can be reversed through various mechanisms involving antigens pathways, immune genetic, and epigenetic pathways. These findings have created a very encouraging foundation for research on the combination of epigenetic and immunotherapeutic drugs as cancer treatments.SUMMARY: The effectiveness of this suggested paradigm can only be demonstrated by clinical studies. Epigenetic treatment might replace immune checkpoint therapy as a powerful new cancer care technique that is generally well tolerated and should be proven with adequate clinical trials.KEYWORDS: epigenetics, immunotherapy, PTM, DNMT, HDAC, immune check point

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 143 tautan kepenulisan bersama · 70 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Hasanuddin University
  • Padjadjaran University
  • PT Prodia StemCell Indonesia (Indonesia)
  • Udayana University
  • University of Indonesia
  • Universitas Trisakti
  • Universitas Airlangga
  • Organisasi lain
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Nurrani Mustika DewiPadjadjaran University90
Suryani As’ádHasanuddin University15
Gatot Susilo LawrenceHasanuddin University7
Yani LinaHasanuddin University6
Ilhamjaya PatellongiHasanuddin University6
Cynthia Retna SartikaPT Prodia StemCell Indonesia (Indonesia)5
Anwar SantosoUdayana University4
Syakib BakriHasanuddin University4
Melisa Intan BarlianaPadjadjaran University4
Keri LestariPadjadjaran University4
Irma Ruslina DefiPadjadjaran University4
Teguh RanakusumaUniversity of Indonesia3
Irawan YusufHasanuddin University3
Rima HaifaPT Prodia StemCell Indonesia (Indonesia)3
Trilis YuliantiHasanuddin University3
Irma Rahayu LatarissaPadjadjaran University3
Ida Paulina SorminHasanuddin University3
Erizal SugionoHasanuddin University3
Keri Lestari DandanPadjadjaran University3
Lucia HerminawatiHasanuddin University3
Yenny SurjawanHasanuddin University2
Mansyur AriefHasanuddin University2
Andri HidayatHasanuddin University2
Ferry SandraUniversitas Trisakti2
Ahmad FariedPadjadjaran University2
Marsetio DonosepoetroUniversitas Airlangga2
Burhanuddin BaharHasanuddin University2
Widjaja LukitoSEAMEO Regional Center for Food and Nutrition2
Indriyanti Rafi SukmawatiHasanuddin University2
Antonia Anna LukitoHasanuddin University2
Mansyur ArifHasanuddin University2
Aziiz Mardanarian RosdiantoPadjadjaran University2
Adziqa Ammara QiantoriPadjadjaran University2
Candra NinghayuHasanuddin University1
Anna MeilanaPadjadjaran University1
Cissy Bana KartasasmitaPadjadjaran University1
Irmansyah IrmansyahNational Research and Innovation Agency1
Terawan Agus PutrantoGatot Soebroto Army Hospital1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Combining Epigenetic and Immunotherapy in Cancer: Molecular Mechanisms</dc:title><dc:creator>Anna Meiliana</dc:creator><dc:creator>Andi Wijaya</dc:creator><dc:subject>epigenetics</dc:subject><dc:subject>cancer immunotherapy</dc:subject><dc:subject>immune checkpoint blockade</dc:subject><dc:subject>PD-1/PD-L1</dc:subject><dc:subject>tumor microenvironment</dc:subject><dc:subject>epigenetic regulators</dc:subject><dc:subject>DNA methyltransferases</dc:subject><dc:subject>histone deacetylase</dc:subject><dc:subject>immune tolerance</dc:subject><dc:subject>combination therapy</dc:subject><dc:description xml:lang="en">BACKGROUND: Immunotherapy, particularly the idea of immune checkpoint blockage is currently draw much attention in cancer treatment. It has been approved as an adjuvant, however, it cannot be a single cancer treatment.CONTENT: The discovery of the basic ligand-receptor interactions between immune and cancer cells inside the tumor microenvironment has led to the current interest in immunotherapy, specifically immune checkpoint inhibition. Different ligands produced by cancer cells interact with immune cells' surface receptors, activating inhibitory pathways, such programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1), that cause immune cells to become immunologically tolerant. On the other side, epigenetic modulators also play a critical role in enhancing the tumor microenvironment and regaining immunological recognition and immunogenicity. Some findings showed that such immune suppression can be reversed through various mechanisms involving antigens pathways, immune genetic, and epigenetic pathways. These findings have created a very encouraging foundation for research on the combination of epigenetic and immunotherapeutic drugs as cancer treatments.SUMMARY: The effectiveness of this suggested paradigm can only be demonstrated by clinical studies. Epigenetic treatment might replace immune checkpoint therapy as a powerful new cancer care technique that is generally well tolerated and should be proven with adequate clinical trials.KEYWORDS: epigenetics, immunotherapy, PTM, DNMT, HDAC, immune check point</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2023-02-23</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>http://dx.doi.org/10.18585/inabj.v15i1.2062</dc:identifier><dc:identifier>10.18585/inabj.v15i1.2062</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 15 No 1 (2023); 1-24</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/2062/616</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>